Mumbai: Indigene Pharmaceuticals (Indigene) and Tata Industries Limited (TIL) announced on Friday that they have entered into a strategic alliance and that TIL has taken a “significant” equity stake in Indigene. Indigene a rapidly growing biopharmaceutical company with its operations in Boston (U.S.), Europe and India, is focused on developing and delivering molecular combination-based products for global prescription and consumer healthcare markets.

TIL is a Tata group company that manages the group’s new initiatives and promoted companies.

Product Development

Speaking on the occasion, Ratan N. Tata, Chairman, TIL, said, “Biotechnology and biopharmaceutical areas offers great potential in creating valve and improving the quality f life for the people around the world. We see a bright a future in the pharmaceutical industry and Indigene, with its unique approach to the product development, technology and a highly reputed global team, is well equipped to meet the challenges of the future.” Founded by M. Vaman Rao in 2002, Indigene Pharmaceuticals has rapidly developed into a new age pharma company with a strategic focus on innovative, safe and effective molecular combination-based products fro both prescription (Rx) and consumer healthcare (CHC) markets.

Indigene is set to launch four CHC products in large self medication areas in the U.S. initially followed by India and other geographies.

Indigene has established an alliance with the Council of Scientific and Industrial Research (CSIR) for developing leads in select disease areas. R. A. Mashelkar, Director General, CSIR, and Secretary, Department of Scientific and Industrial Research (DSIR), called for new age pharma approach.